Vicasinabin structure
|
Common Name | Vicasinabin | ||
|---|---|---|---|---|
| CAS Number | 1433361-02-4 | Molecular Weight | 358.40 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C15H22N10O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VicasinabinVicasinabin is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1)[1]. |
| Name | Vicasinabin |
|---|
| Description | Vicasinabin is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1)[1]. |
|---|---|
| Related Catalog | |
| Target |
CB2[1] |
| References |
[1]. Jean-Michel Adam, et al. Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives. Patent US20130116236A1. |
| Molecular Formula | C15H22N10O |
|---|---|
| Molecular Weight | 358.40 |